Biotech & Pharma Sector Snapshot — Provenance by Kaleidoscope

Sector Aggregates

Across 822 tracked companies in chemicals and life sciences (SIC 28xx), the average echo composite sits at -9.50 — firmly negative. Distress language is outweighing positive signals at the sector level, with fewer than 1 in 5 companies showing a net-positive echo profile.

-9.50

Avg Echo Composite

7.67

Avg Distress Echo

15.59

Avg Positive Echo

20.9%

% Positive Echo Companies

0.52

Avg Profile Mutation

199.4

Avg Entropy Surprise

46.5

Avg Classifiers Fired

822

Companies Tracked

Sector read: The average composite is firmly negative (-9.50), meaning distress signals outweigh positive ones across the sector on an echo-weighted basis. Only ~21% of companies are showing net-positive echo profiles. The average mutation of 0.52 is moderate — about half the sector's filing profiles are shifting materially from their historical baselines.

Highest Echo Composite

Companies with the strongest signal activity — the highest total echo score across all classifiers, regardless of direction.

#	Company	Echo Composite	Classifiers Fired	Read
1	UL Unilever	114.05	27	High echo, few classifiers — intense but focused signals
2	BAK Braskem	92.15	19	Very high composite, narrowest classifier set — concentrated signal
3	ACB Aurora Cannabis	25.70	14	Cannabis sub-sector; also appears in distress list
4	SNDL Sundial Growers	19.75	56	Broadest classifier storm in the top 5 — 56 classifiers firing
5	QGEN Qiagen	15.60	35	Also #1 in distress — composite dominated by stress signals

UL and BAK are extreme outliers — very high composites with relatively few classifiers firing means the signals that are hitting are doing so with very high echo (persistent, unusual language shifts). SNDL with 56 classifiers is a broad signal storm: many themes firing at once, not a concentrated pivot.

Most Distressed

Companies with the highest distress echo score — persistent, unusual distress language relative to their own filing history.

#	Company	Distress Echo	Note
1	QGEN Qiagen	124.0	Also in top-5 composite — filing profile dominated by stress
2	MCUJF Medicure	118.0	Small-cap pharma; high distress relative to size
3	ACB Aurora Cannabis	108.0	Cross-listed; consistent cash and profitability pressure
4	EVGN Evogene	87.0	Computational biology; pipeline-stage pressure
5	NYMXF Nymox Pharma	87.0	Late-stage BPH program; ongoing cash burn signals

QGEN leads distress — notable because it also appears in the highest composite list, meaning its filing profile is dominated by stress signals. The cannabis names (ACB, SNDL) appearing in both distress and high-composite lists is consistent with ongoing sector-wide cash and profitability pressure in that sub-industry.

Highest Profile Mutation

Companies whose current filing language bears the least resemblance to their own historical baseline. A score of 1.0 means maximum divergence from prior patterns.

#	Company	Mutation Score	Why It Matters
1	ABT Abbott Labs	1.00 — Max	Large-cap at max mutation — material strategic shift likely
2	ELDN Eledon Pharma	1.00 — Max	Small-cap; pipeline or corporate structure change
3	ELF e.l.f. Beauty	1.00 — Max	Consumer/beauty crossover; filing language fully shifted
4	MESO Mesoblast	1.00 — Max	Cell therapy; possible regulatory or approval inflection
5	NVO Novo Nordisk	1.00 — Max	GLP-1 megacap at max mutation — GLP-1 scale, M&A, or pipeline pivots

All five are at maximum mutation (1.0) — their current filing profiles bear no resemblance to their own historical norms. ABT and NVO are large-caps, so full mutation there is especially notable and may warrant a closer look. MESO (cell therapy) hitting max mutation could reflect a regulatory or pipeline inflection. When large-caps mutate, it tends to be structural — M&A, strategic pivots, or the onset of a new growth regime.

Analyst Summary

The biotech and pharma sector is running net-negative with broad distress. The cannabis sub-sector (ACB, SNDL) remains under sustained financial pressure — both names appear across multiple negative signal lists.

The more interesting signals are the max-mutation large-caps. Abbott Labs and Novo Nordisk are filing in ways completely unlike their historical patterns. For NVO, GLP-1 scale and the associated pipeline and M&A activity likely explains the shift. For ABT, the driver is less obvious and may warrant a closer look at their most recent 10-K language.

QGEN is the single most distressed name in the sector, notable because it surfaces in both the distress list and the high-composite list — its filing profile is dominated by stress language, not noise.

Signal Methodology

Sector snapshots are generated by running Provenance's 529-classifier system across all companies in a SIC grouping and aggregating the per-company signal scores. Echo composite is the sum of all classifier echo scores — positive classifiers add, negative ones subtract. Distress echo isolates classifiers in the distress family (going concern, liquidity stress, covenant pressure, etc.).

Profile mutation measures how different a company's current filing language is from its own historical baseline, scored 0–1. A score of 1.0 means the current profile is maximally dissimilar to prior filings. Entropy surprise reflects the unexpectedness of the current classifier distribution given historical patterns. Both are derived from the ARGOS cascade pipeline.

Data sourced from SEC EDGAR via Provenance. Coverage: 2026 filings, primary window Mar 2026.